



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/699,003
Filing Date	October 26, 2009
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3761
Examiner Name	Leslie R. Deak
Attorney Docket Number	LEN 101 CIP CON

**U.S. PATENT DOCUMENTS**

---

**FOREIGN PATENT DOCUMENTS**

---

Signature /Leslie Deak/ Date 11/12/2009

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached *Index of U.S. Patent Documents*. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2009
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3761
Examiner Name	Leslie R. Deak
Attorney Docket Number	LEN 101 CIP CON

Sheet 2 of 3

## OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity", <i>Cytokine</i> , 4(3):180-184 (1992).	
		BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors: soluble receptor forms", <i>Lymphokine Cytokine Res.</i> , 13(3):203-11 (1994).	
		COLMAN, et al., <i>Haemostasis and Thrombosis: Basic Principles and Clinical Practice</i> 2nd Ed., Colman, R.W., et al., p. 242-267 (J.B. Lippincott, Philadelphia, PA 1987).	
		GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNF), and soluble CD14 (sCD14) in epithelial ovarian cancer", <i>Gynecol Oncol</i> , 58(2):184-8 (1995).	
		GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", <i>Proc Natl Acad Sci U S A</i> , 95(2):570-5 (1998).	
		GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", <i>Gynecol Oncol</i> , 50(1):68-77 (1993).	
		HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", <i>Gerontology</i> , 46(4):185-8 (2000).	
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients", <i>Arch Immunol Ther Exp (Warsz)</i> , 45(5-6):449-53 (1997).	
		JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", <i>Eur Cytokine Netw</i> , 9(2):155-9 (1998).	
		LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con <i>Trypanosoma cruzi</i> " <i>Revista Argentina de Microbiología</i> , 28:99-109 (1996) (with English Abstract).	
		MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", <i>J Recept Signal Transduct Res</i> , 17(1-3):521-9 (1997). (with English Abstract)	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

45100091

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /LD/

07829/0009

Receipt date: 11/10/2009

Please type a plus sign (+) inside this box →

+

PTO/SB/068A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	09/699,003
Filing Date	October 26, 2009
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3761
Examiner Name	Leslie R. Deak
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Signature	/Leslie Deak/	Date Considered	12/03/2009
----------------------	---------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication or application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached *Kinds of U.S. Patent Documents*. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO STANDARD ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO STANDARD ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.